Specifically, the median PFS in lung cancer and adenocarcinoma patients with low SCD expression was 27.14 and 41.4 months, respectively, and was 12.1 and 18.63 months, respectively, in patients with high SCD expression. The gene discussed is SCD; the disease is lung carcinoma.